3Kapil R,Nolting A,Roy P,et al.Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen:two randomized,open-label,crossover studies in healthy adult volunteers.Clin Ther,2004,26(12):2015-2025. 被引量：1
4Schrijvers D.Pain control in cancer:recent findings and trends.Ann Oncol,2007,18 Suppl 9:ix37-42. 被引量：1
5Salzman RT,Roberts MS,Wild J,et al.Can a controlled-release oral dose form of oxycodone be used as readily as an immediate-release form for the purpose of titrating to stable pain control.J Pain Symptom Manage,1999,18(4):271-279. 被引量：1
6Trescot AM,Glaser SE,Hansen H,et al.Effectiveness of opioids in the treatment of chronic non-cancer pain.Pain Physician,2008,11(2 Suppl):S181-200. 被引量：1
7Suzuki T,Morishita M,Ito E,et al.Analgesic efficacy of controlled-release oxycodone in patients with uterine or ovarian cancer.Am J Ther,2008,15(1):31-35. 被引量：1
8Czarnecki ML,Jandrisevits MD,Theiler SC,et al.Controlled-release oxycodone for the management of pediatric postoperative pain.J Pain Symptom Manage,2004,27(4):379-386. 被引量：1
9De Luca A,Coupar IM.Insights into opioid action in the intestinal tract.Pharmacol Ther,1996,69(2):103-115. 被引量：1
